President's Message


I am very excited to be addressing you all for the first time as the Greater New York Chapter Board President. I feel honored to take on this new role and am looking forward to the next two years. With that said, it is with great pleasure that I am able to welcome our 3 new members for the 2015-2016 term, Brian Gonick, Michael Schultz, and Marc S. Hurlbert, PhD. Each of these individuals have a great deal to contribute to the Greater New York Chapter and our pursuit to fulfill the mission of the Cystic Fibrosis Foundation.

On July 2nd, The Cystic Fibrosis Foundation celebrated the Food and Drug Administration’s approval of the lumacaftor/ivacaftor combination drug, Orkambi™. This is an extremely important advancement for the cystic fibrosis community. Orkambi targets the underlying cause of the disease in people with two copies of the most common CF gene mutation.

The FDA approved the drug for people with CF ages 12 and older who have two copies of the F508del mutation, representing 8,500 people or nearly one-third of the CF population in the United States. However, nearly half of individuals with CF have two copies of this mutation and could eventually benefit from the therapy after the drug is approved for younger patients.

I think Dr. Bob Beall, President and CEO of the CF Foundation, summed up this exciting news well when he stated, “It is our hope that everyone who is prescribed this drug will have immediate access to it so they can begin to live longer, healthier lives.”

Over the past several months the Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), a nonprofit affiliate of the Cystic Fibrosis Foundation has announced multiple partnerships and awards focused on the Foundation’s therapeutics pipeline. Most recently, on April 22nd, CFFT announced a $5 million development award to Corbus Pharmaceuticals for a potential new therapy to reduce lung inflammation in people with CF. The award will help fund a Phase 2 clinical trial of Resunab, a novel synthetic oral drug. Resunab has the potential to address inflammation in people with CF, regardless of an individual’s CF gene mutations.

To learn more about the FDA’s recent approval of Orkambi™ or the CFFT’s awards, please visit the “News & Events” section of CFF.org.


Robert J. Corti
President, Board of Directors